Chrexanthomycin C, an orally active marine-derived natural product, exhibits significant bioactivities and shows a binding affinity for DNA [(G4C2)4 G4] with a dissociation constant (Kd) of 2.8 mM. This compound holds potential for neurodegenerative disease research, including amyotrophic lateral sclerosis (ALS) [1].